Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Myonecrosis after revascularization procedures

R M Califf1, A E Abdelmeguid, R E Kuntz

  • 1Department of Anesthesiology, Duke University Medical Center, Durham, North Carolina, USA. calif001@mc.duke.edu

Journal of the American College of Cardiology
|February 14, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Zalunfiban at First Medical Contact for ST-Elevation Myocardial Infarction.

NEJM evidence·2025
Same author

Cardiac troponin is associated with cardiac outcomes in men and women with atrial fibrillation, insights from the ARISTOTLE trial.

Journal of internal medicine·2020
Same author

Patient and caregiver reported facilitators of self-care among patients with chronic heart failure: report from a formative qualitative study.

Wellcome open research·2020
Same author

Psychosocial stress and major cardiovascular events in patients with stable coronary heart disease.

Journal of internal medicine·2017
Same author

Department of Error.

Lancet (London, England)·2015
Same author

D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation--observations from the ARISTOTLE trial.

Journal of thrombosis and haemostasis : JTH·2014
Same journal

Aortic Valve Replacement in Women of Reproductive Age.

Journal of the American College of Cardiology·2026
Same journal

Sudden Death in Cardio-Kidney-Metabolic Patients: Insights From FINE-HEART.

Journal of the American College of Cardiology·2026
Same journal

Ultra-Thin Sirolimus-Eluting Versus Everolimus-Eluting Stents in Diabetic Multivessel Coronary Artery Disease Patients: The TUXEDO-2 Trial.

Journal of the American College of Cardiology·2026
Same journal

Reframing Cardiometabolic Risk and Frailty Through Sarcopenic Obesity.

Journal of the American College of Cardiology·2026
Same journal

Imaging-Derived Sarcopenic Obesity and Cardiovascular Outcomes: Insights Into Heart Failure Risk and Muscle Biology.

Journal of the American College of Cardiology·2026
Same journal

The Measure of a Leader: Lessons in Leadership From Eugene Braunwald.

Journal of the American College of Cardiology·2026
See all related articles

Elevated cardiac enzymes (CK or CK-MB) after revascularization, including percutaneous intervention and CABG, are linked to higher mortality and adverse cardiac events. Any enzyme elevation, not just Q wave changes on ECG, indicates increased risk.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Biomarkers

Background:

  • Elevated cardiac enzyme levels and ECG abnormalities post-revascularization are debated.
  • Creatine kinase (CK) or CK-MB isoenzyme (CK-MB) elevations occur in 5-30% of patients after percutaneous intervention and commonly after CABG.

Purpose of the Study:

  • To achieve consensus on the significance of cardiac enzyme elevations and ECG changes after revascularization.
  • To clarify the prognostic implications of periprocedural myocardial necrosis.

Main Methods:

  • Analysis of data from over 10,000 patients undergoing percutaneous intervention.
  • Review of existing studies on cardiac enzyme and ECG changes after revascularization (PCI and CABG).

Main Results:

Related Experiment Videos

  • CK or CK-MB elevation is associated with higher mortality, subsequent cardiac events, and increased costs.
  • Risk of adverse outcomes increases with any CK or CK-MB elevation, proportionally to intervention level.
  • ECG changes, particularly Q waves, are rare; most events lack definitive ECG diagnosis.

Conclusions:

  • Recommended: Pre- and post-procedural ECGs and serial cardiac enzyme measurements.
  • Patients with >3-fold enzyme elevation or Q wave MI criteria should be treated as MI.
  • Further research needed to confirm enzyme elevation as an independent risk factor and assess impact of interventions reducing enzyme release.